Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director · Bd. Co-Chair, President & CSO | December 31, 2025 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 31, 2025 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 310,460 |
Ending reported balance
After 2025-12-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-12-31 · Exercise / conversion · Acquired 28,570 · Balance 339,030 Row 2 · 2025-12-31 · Tax withholding · Disposed 28,570 · Balance 310,460 |
| 2020 Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 595,077 |
Reported balance
After 2025-12-31 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-12-31 · Exercise / conversion · Disposed 28,570 · Balance 595,077 F2: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company. |
| Common StockSEC Table I · non-derivative | IndirectBy 2024 GRAT | 71,487 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 71,487 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT | 200,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 200,000 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT II | 200,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 200,000 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 5,962 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,962 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust for Chldn. | 180,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 180,000 F1: As investment trustee of trusts for the benefit of the reporting person's children. |
| Common StockSEC Table I · non-derivative | Indirectby 2024 GRAT II | 101,988 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 101,988 |
| Common StockSEC Table I · non-derivative | Indirectby Children | 56,048 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 56,048 |
Filing footnotes · ownership attribution and instrument terms
F1: As investment trustee of trusts for the benefit of the reporting person's children.
F2: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 21, 2016 Filed Dec 19, 2016 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-16-000087 · edgardoc.xml · nonDerivative · entry 4 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President Regeneron Laboratori 10b5-1 filing: Not disclosed Ownership: Indirect · by GRAT Disclosed balance after: 500,000 Read SEC document |
| December 17, 2015 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,921 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 13 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 569,897 Read SEC document |
| December 17, 2015 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,921 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Read SEC document |
| November 02, 2015 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 43,348 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 12 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 612,936 Read SEC document |
| November 02, 2015 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 43,348 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.